MA38323A1 - Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale - Google Patents
Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie viraleInfo
- Publication number
- MA38323A1 MA38323A1 MA38323A MA38323A MA38323A1 MA 38323 A1 MA38323 A1 MA 38323A1 MA 38323 A MA38323 A MA 38323A MA 38323 A MA38323 A MA 38323A MA 38323 A1 MA38323 A1 MA 38323A1
- Authority
- MA
- Morocco
- Prior art keywords
- amelioration
- prevention
- treatment
- viral disease
- pyrimidone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La présente invention concerne un composé de formule générale (i), éventuellement sous la forme d'un sel, solvate, polymorphe, comédicament, cocristal, promédicament, tautomère, racémique, énantiomère ou diastéréoisomère pharmaceutiquement acceptable ou d'un mélange de ceux-ci, qui sont utiles dans le traitement, l'amélioration ou la prévention d'une maladie virale. De plus, l'invention concerne des polythérapies spécifiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361750017P | 2013-01-08 | 2013-01-08 | |
PCT/EP2014/050165 WO2014108406A1 (fr) | 2013-01-08 | 2014-01-07 | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38323A1 true MA38323A1 (fr) | 2017-02-28 |
MA38323B1 MA38323B1 (fr) | 2018-05-31 |
Family
ID=50070507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38323A MA38323B1 (fr) | 2013-01-08 | 2014-01-07 | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale |
Country Status (21)
Country | Link |
---|---|
US (1) | US9045486B2 (fr) |
EP (1) | EP2943495B1 (fr) |
JP (1) | JP2016518305A (fr) |
KR (1) | KR20150103285A (fr) |
CN (1) | CN104918942A (fr) |
AR (1) | AR094378A1 (fr) |
AU (1) | AU2014204889A1 (fr) |
BR (1) | BR112015012693A2 (fr) |
CA (1) | CA2894642A1 (fr) |
CL (1) | CL2015001916A1 (fr) |
CR (1) | CR20150337A (fr) |
EA (1) | EA201591291A1 (fr) |
HK (2) | HK1211286A1 (fr) |
IL (1) | IL239656A0 (fr) |
MA (1) | MA38323B1 (fr) |
MX (1) | MX2015008293A (fr) |
PE (1) | PE20151722A1 (fr) |
PH (1) | PH12015501517A1 (fr) |
SG (1) | SG11201503946UA (fr) |
TW (1) | TW201443053A (fr) |
WO (1) | WO2014108406A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
IL239682B (en) | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
EP3030566B1 (fr) | 2013-09-12 | 2020-07-08 | Janssen BioPharma, Inc. | Dérivés de 7,8-dihydro-3h-pyrazino[1,2-b]pyridazine-3,5(6h)-dione et leurs utilisations |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
EP3268368A4 (fr) | 2015-03-11 | 2018-11-14 | Alios Biopharma, Inc. | Composés d'aza-pyridone et leurs utilisations |
JP5971830B1 (ja) | 2015-04-28 | 2016-08-17 | 塩野義製薬株式会社 | 置換された多環性ピリドン誘導体およびそのプロドラッグ |
CN107709321A (zh) | 2015-04-28 | 2018-02-16 | 盐野义制药株式会社 | 经取代的多环性吡啶酮衍生物及其前药 |
TW201726678A (zh) | 2015-10-30 | 2017-08-01 | 赫孚孟拉羅股份公司 | 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途 |
CN108697715A (zh) | 2015-12-15 | 2018-10-23 | 盐野义制药株式会社 | 包含帽依赖性核酸内切酶抑制剂及抗流感药的组合的流感治疗用药物 |
WO2017109088A1 (fr) | 2015-12-23 | 2017-06-29 | Savira Pharmaceuticals Gmbh | Dérivés pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale |
EP3426656B1 (fr) | 2016-03-08 | 2021-05-12 | Novartis AG | Composés tricycliques utiles pour traiter des infections à orthomyxovirus |
WO2017158151A1 (fr) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale |
WO2017158147A1 (fr) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Dérivés de pyrimidone et leur utilisation pour le traitement, la prévention ou l'atténuation des symptômes d'une maladie virale |
JP6961963B2 (ja) * | 2016-04-01 | 2021-11-05 | 三菱ケミカル株式会社 | フルフラールの製造方法 |
WO2017198744A1 (fr) * | 2016-05-20 | 2017-11-23 | F. Hoffmann-La Roche Ag | Nouveaux composés de pyrazine ayant un coupleur d'oxygène, de soufre et d'azote pour le traitement de maladies infectieuses |
KR102424709B1 (ko) | 2016-05-31 | 2022-07-22 | 칼비스타 파마슈티컬즈 리미티드 | 혈장 칼리크레인 저해제로서 피라졸 유도체 |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
WO2018030463A1 (fr) | 2016-08-10 | 2018-02-15 | 塩野義製薬株式会社 | Dérivé de pyridone polycyclique substitué et composition pharmaceutique contenant un promédicament de celui-ci |
JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
PL3716952T3 (pl) | 2017-11-29 | 2022-05-02 | Kalvista Pharmaceuticals Limited | Postacie dawkowania zawierające inhibitor kalikreiny osoczowej |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
CN111801333A (zh) | 2018-02-28 | 2020-10-20 | 诺华股份有限公司 | 作为正粘病毒复制抑制剂用于治疗流感的10-(二(苯基)甲基)-4-羟基-8,9,9a,10-四氢-7H-吡咯并[1’,2’:4,5]吡嗪并[1,2-b]哒嗪-3,5-二酮衍生物及相关化合物 |
WO2021028645A1 (fr) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
EP4126242A1 (fr) * | 2020-03-25 | 2023-02-08 | SRI International | Inhibiteurs tricycliques de l'endonucléase du virus de la grippe |
EP4074317A1 (fr) | 2021-04-14 | 2022-10-19 | Bayer AG | Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1 |
WO2024061300A1 (fr) * | 2022-09-22 | 2024-03-28 | Insilico Medicine Ip Limited | Inhibiteurs de trex1 et utilisations associées |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
EP1725554A1 (fr) * | 2004-03-09 | 2006-11-29 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Inhibiteurs de l'int grase du vih |
US7550463B2 (en) | 2004-09-15 | 2009-06-23 | Shionogi & Co., Ltd. | Carbamoylpyridone derivatives having inhibitory activity against HIV integrase |
WO2006125048A2 (fr) | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Composes inhibant l'integrase |
EP1906971A2 (fr) * | 2005-07-27 | 2008-04-09 | Gilead Sciences, Inc. | Composes antiviraux |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
WO2010110231A1 (fr) | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | Dérivé de 3-hydroxy-4-pyridone substitué |
WO2010147068A1 (fr) | 2009-06-15 | 2010-12-23 | 塩野義製薬株式会社 | Dérivé de carbamoylpyridone polycyclique substituée |
WO2011000566A2 (fr) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Composés et compositions pharmaceutiques pour le traitement de dinfections virales à arn simple brin, sens négatif |
TR201810736T4 (tr) * | 2010-09-24 | 2018-08-27 | Shionogi & Co | Substitüe polisiklik karbamoil piridon derivatı ön-ilacı. |
-
2014
- 2014-01-07 JP JP2015551199A patent/JP2016518305A/ja active Pending
- 2014-01-07 CA CA2894642A patent/CA2894642A1/fr not_active Abandoned
- 2014-01-07 BR BR112015012693A patent/BR112015012693A2/pt active Search and Examination
- 2014-01-07 CN CN201480004139.1A patent/CN104918942A/zh active Pending
- 2014-01-07 KR KR1020157021361A patent/KR20150103285A/ko not_active Application Discontinuation
- 2014-01-07 AU AU2014204889A patent/AU2014204889A1/en not_active Abandoned
- 2014-01-07 US US14/149,284 patent/US9045486B2/en not_active Expired - Fee Related
- 2014-01-07 PE PE2015001253A patent/PE20151722A1/es not_active Application Discontinuation
- 2014-01-07 WO PCT/EP2014/050165 patent/WO2014108406A1/fr active Application Filing
- 2014-01-07 MX MX2015008293A patent/MX2015008293A/es unknown
- 2014-01-07 SG SG11201503946UA patent/SG11201503946UA/en unknown
- 2014-01-07 EP EP14703275.9A patent/EP2943495B1/fr not_active Not-in-force
- 2014-01-07 EA EA201591291A patent/EA201591291A1/ru unknown
- 2014-01-07 MA MA38323A patent/MA38323B1/fr unknown
- 2014-01-07 AR ARP140100051A patent/AR094378A1/es unknown
- 2014-01-08 TW TW103100719A patent/TW201443053A/zh unknown
-
2015
- 2015-06-25 IL IL239656A patent/IL239656A0/en unknown
- 2015-06-25 CR CR20150337A patent/CR20150337A/es unknown
- 2015-07-03 PH PH12015501517A patent/PH12015501517A1/en unknown
- 2015-07-06 CL CL2015001916A patent/CL2015001916A1/es unknown
- 2015-12-08 HK HK15112095.2A patent/HK1211286A1/xx unknown
-
2016
- 2016-01-19 HK HK16100546.1A patent/HK1212686A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2943495B1 (fr) | 2016-12-28 |
CA2894642A1 (fr) | 2014-07-17 |
US9045486B2 (en) | 2015-06-02 |
TW201443053A (zh) | 2014-11-16 |
AU2014204889A1 (en) | 2015-06-11 |
CN104918942A (zh) | 2015-09-16 |
AR094378A1 (es) | 2015-07-29 |
BR112015012693A2 (pt) | 2017-07-11 |
WO2014108406A1 (fr) | 2014-07-17 |
PE20151722A1 (es) | 2015-11-19 |
CR20150337A (es) | 2015-11-02 |
MA38323B1 (fr) | 2018-05-31 |
PH12015501517A1 (en) | 2015-11-09 |
CL2015001916A1 (es) | 2016-01-22 |
KR20150103285A (ko) | 2015-09-09 |
MX2015008293A (es) | 2016-06-02 |
EA201591291A1 (ru) | 2015-12-30 |
EP2943495A1 (fr) | 2015-11-18 |
IL239656A0 (en) | 2015-08-31 |
US20140194431A1 (en) | 2014-07-10 |
HK1212686A1 (zh) | 2016-06-17 |
SG11201503946UA (en) | 2015-09-29 |
JP2016518305A (ja) | 2016-06-23 |
HK1211286A1 (en) | 2016-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
MX2014014109A (es) | Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral. | |
MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
MA37405A1 (fr) | Composés hétérocyclyle | |
PH12016500359A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
MY166866A (en) | Heterocyclic derivative and pharmaceutical drug | |
WO2008094909A3 (fr) | Composés de quinazolinone et de pyrimidinone fusionnés et leur utilisation dans le traitement de maladies ou d'affections induites par les canaux sodiques | |
EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
MA38138A1 (fr) | Dérivés inédits de quinolone | |
MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
EA201491283A1 (ru) | Ингибитор регулирующей апоптотические сигналы киназы | |
MX2018009944A (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico. | |
MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
EA200900178A1 (ru) | Конденсированные гетероциклические производные и их применение | |
TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
JP2019524883A5 (fr) | ||
MX342176B (es) | Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
TN2017000158A1 (en) | Carbazole derivatives | |
MX2014003803A (es) | Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
MA39983B1 (fr) | Dérivés de carboxamide | |
WO2008109856A3 (fr) | Procédés de traitement de maladies ou d'affections associées aux canaux à sodium au moyen de composés de type diazépinone. | |
PH12020551713A1 (en) | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators |